BioSpace News Archive

HTA ended Q2 2019 with net income attributable to common stockholders of $0.08 per diluted share, Normalized FFO of $0.41 per diluted share, Same-Property Cash NOI growth of 2.9% and has completed $111 million of investments to date.

Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq: APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended June 30, 2019.

Among Its Valuable Features Are A Revenue Impact Analyzer and Case-Mix Impact Analyzer

Global Cord Blood Corporation, China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, announced that the Company filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of an agreement with Ab Initio Biotherapeutics whereby Ligand will acquire Ab Initio for $12 million in cash.

Sales grew 15% to $1.1 billion; underlying1 sales grew 14%

LifeSpan BioSciences, Inc. (LSBio™), the industry leader in molecular pathology, today announced the first release of its PathPlusTM series of antibodies.

Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced that LIBERTY 2, the second of two Phase 3 studies of once-daily relugolix combination therapy, met its primary efficacy endpoint and six key secondary endpoints in women with uterine fibroids

Both models feature USB3 Vision interfaces, whose combination of bandwidth and easy plug-and-play compatibility have made it a widely-used choice for microscopy systems.

RCCA MSO LLC, the management services entity for Regional Cancer Care Associates LLC and RCCA MD LLC became aware of suspicious activity regarding an employee email account.